Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy

Thomas A. Premeaux, Carlee B. Moser, Ashley McKhann, Martin Hoenigl, Elizabeth I. Laws, Draven L. Aquino, Michael M. Lederman, Alan L. Landay, Sara Gianella, Lishomwa C. Ndhlovu, for the Adult Clinical Trials Group NWCS 411 Study Team

Background: People with HIV (PWH) on antiretroviral therapy (ART) still experience an increased risk of morbidity and mortality, presumably driven by chronic inflammation, yet predictors of discrete or combinatorial outcomes remain unclear. Galectin-9 (Gal-9), a driver of both inflammatory and immunosuppressive responses, has been associated with HIV disease progression and multimorbidity.

Objective: To determine whether plasma Gal-9 levels are associated with the occurrence of specific non-AIDS events (NAEs) in PWH initiating ART.

Design: We performed a nested case–control study of PWH enrolled from 2001 to 2009 and evaluated pre-ART (66 cases, 97 controls), a year post-ART (112 cases, 211 controls), and immediately preceding an event (89 cases, 162 controls). Events included myocardial infarction/stroke, malignancy, serious bacterial infection, or death.

Methods: Plasma Gal-9 levels were assessed by ELISA. Conditional logistic regression assessed associations with NAEs and Spearman’s correlations compared Gal-9 with other previously assessed biomarkers.

Results: NAEs occurred at a median of 2.8 years (1.7–4.6) after ART initiation. Higher Gal-9 levels were associated with increased risk of NAEs at year 1 and pre-event [odds ratio (OR) per 1 interquartile range = 1.4–1.6; all P < 0.05], specifically myocardial infarction/stroke at year 1 (OR = 1.9; P = 0.029). Gal-9 also correlated with multiple inflammatory and immune activation predictors of NAEs (all timepoints).
Conclusion: Elevated Gal-9 levels are predictive of deleterious NAEs, particularly cardiovascular complications. Whether the Gal-9 pathway, potentially binding to its putative ligands, is active in the pathogenesis of these outcomes warrants further investigation to determine if targeting Gal-9 may slow or reverse the risk of NAEs.

Keywords: antiretroviral therapy, biomarkers, galectins, HIV, morbidity, viral suppression

Introduction

People with HIV (PWH) experience non-AIDS events (NAEs), such as cardiovascular disease, non-AIDS-defining malignancies, and mortality, earlier and at a higher rate than people without HIV despite the use of antiretroviral therapy (ART) [1,2]. Persistent inflammation and immune activation are hallmarks of HIV infection and are thought to be significant contributors to these comorbid events [3,4], and the cause of this chronic inflammation is likely multifactorial and varies by individual and over time [3]. Although several markers of inflammation, coagulation, and immune activation are predictive of NAEs [5,6], mechanisms involved in the progression of morbidities in HIV is still not fully understood.

Glycoimmunology, glycan–lectin interactions governing immune responses, is an emerging field in host–pathogen research, with several glycan and lectin members historically being associated with HIV pathogenesis [7,8]. Galectin-9 (Gal-9), a glycan-binding immunomodulatory protein, is elevated in plasma of PWH on ART [9] and associates with pathogenesis, increased risk of mortality, and the extent of multimorbidity [10–12]. Gal-9 has been linked to several age-related complications in the general population, including cardiovascular, kidney, and liver dysfunction [13–16], and proposed as a promising biomarker for various cancers and autoimmune diseases [17–24]. Given the pleiotropic nature of Gal-9 in immunosuppression and inflammation [25–31], and in line with studies on HIV pathogenesis and morbidity, the significance of Gal-9 in the occurrence of NAEs warrants consideration.

To investigate the predictive efficacy of plasma Gal-9 for NAEs, we conducted a case–control study of participants enrolled in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) [32], evaluated prior to ART, 1 year after ART initiation, and a timepoint prior to an NAE. We also explored potential Gal-9 relationships with pre-ART factors and biomarkers previously linked to NAEs. Further elucidating novel biomarkers, such as Gal-9, that track immune perturbations and associate with NAEs will help identify and/or monitor interventions aimed to reduce morbidity and mortality in PWH on effective ART.

Methods

Cohort descriptions

NWCS 411 is an ALLRT-nested case–control study to examine potential predictive biomarkers and their relationships with NAEs in PWH enrolled from 2001 to 2009 [32]. This study builds off a previous case–control study, NWCS 329, which found associations between several biomarkers of immune activation and NAEs [6]. NAEs in participants (cases) include myocardial infarction/stroke, malignancy, serious bacterial infections, or mortality. For each case, 1–3 participants (controls) with an event-free follow-up equal or greater than the relevant case, were matched for age, sex, pre-ART CD4+ T-cell count, and ART regimen. All participants were ART-naive when enrolled and had plasma HIV RNA less than 400 copies/ml a year post-ART initiation.

Galectin-9 quantification

Stored plasma aliquots were measured for Gal-9 in duplicate using the solid-phase Human Galectin-9 Quantikine ELISA kit (R&D Systems, Minneapolis, Minnesota, USA) according to manufacturer’s instructions. Optical density was read with a microplate spectrophotometer (Bio-Rad, Hercules, California, USA) and data analysis, including four parameter logistic standard interpolation, was carried out using MyAssays Ltd. data analysis. Average intra-assay coefficient of variation (CV) was 4.11% and inter-assay CV was 9.95%.

Statistical analyses

Demographic and clinical characteristics are presented using median (IQR) for continuous variables and frequency for categorical variables. Baseline to year 1 Gal-9 distributions were compared using Wilcoxon matched-pairs signed rank test to calculate P values and Hodges–Lehmann estimate of the location shift (with 95% CI). Conditional logistic regression analysis assessed associations of Gal-9 and NAEs in models unadjusted and adjusted for pertinent covariates at every timepoint. As participants were matched by pre-ART CD4+ T-cell count and suppressed by week 48, adjusted analyses considered HIV-RNA levels at baseline and CD4+ count for postbaseline analyses. Relationships among biomarkers at each timepoint among controls were assessed by Spearman correlations. Soluble
markers were log_{10} transformed prior to analyses. All statistical tests used a two-sided 5% type-I error rate, without adjustment for multiple testing, and were performed in SAS version 9.4 (SAS Institute, Cary, North Carolina, USA).

## Results

### Cohort and plasma galectin-9 distributions
Three time points were considered in this analysis: baseline (pre-ART; 66 cases, 97 controls), a year post-ART initiation (112 cases, 211 controls), and immediately preceding an event (89 cases, 162 controls). Overall, 84% of participants were men, median (Q1–Q3) age was 45 (39–51) years, CD4+ T-cell count was 213 (79–334) cells/µL, and plasma HIV RNA was 4.8 (4.4–5.4) log_{10} copies/ml (Table 1). CD4+ T-cell count at year 1 for controls and cases were 404 (269–561) and 347 (229–479) cells/µL, respectively, reflecting an expected rebound of counts after ART initiation. NAEs occurred at a median of 2.8 years (1.7–4.6) after ART initiation and 10.5 (6.1–19) weeks from the preevent timepoint. Among cases, 13.4% were nonaccidental deaths (n = 18), 28.4% were myocardial infarction (MI)/strokes (n = 38), 37.3% were malignancies (n = 50), and 26.9% were serious bacterial infections (n = 36). Distributions of plasma Gal-9 among cases and controls at each timepoint are shown in Fig. 1a. Baseline plasma Gal-9 levels were similar for cases and controls; median value 15.39 (IQR 10.35–24.61) and 15.00 (10.05–24.03) µg/mL, respectively. As previously observed [33], plasma Gal-9 levels after ART initiation (year 1) differed significantly compared with baseline values, here in cases [95% CI = 0.20 (0.13–0.27), P < 0.001] and to a greater extent in controls [95% CI = 0.28 (0.22–0.33), P < 0.001].

### Galectin-9 associations with pre-antiretroviral therapy factors and previously assessed biomarkers among controls
Higher Gal-9 levels at baseline were correlated with higher HIV RNA (r = 0.49, P < 0.0001) and with lower CD4+ T-cell counts (r = -0.58, P < 0.0001), as previously reported (Fig. 1b, Supplementary Table 1, http://links.lww.com/QAD/C257) [34]. We also found several strong associations between plasma Gal-9 and previously analyzed biomarkers. Baseline levels of Gal-9 highly correlated with interleukin-6 (IL-6), soluble tumor necrosis factor receptor (sTNFR) I and II, soluble urokinase plasminogen activator receptor (suPAR), sCD14, interferon gamma-induced protein 10, and D-dimer (all r ≥ 0.45, P < 0.0001), and were moderately associated with 1,3-β-D-glucan (BDG), liposaccharide-binding protein, intestinal fatty-acid binding protein, and sCD163 (all r = 0.22–0.36, P ≤ 0.008). Strong associations among Gal-9 with sTNFR-I, sTNFR-II, and suPAR remained at year 1 post-ART initiation and preevent (all r ≥ 0.45, P < 0.0001).

### Galectin-9 as a predictor of non-AIDS events
Higher plasma levels of Gal-9 were associated with having a NAEs at year 1 (unadjusted odds ratio (OR) per 1 IQR = 1.4; 95% CI, 1.0–1.9; P = 0.036) and preevent (OR = 1.6, 1.0–2.3; P = 0.029) (Fig. 1c). Although not statistically significant, a similar effect size was observed at

---

**Table 1. Cohort demographic and clinical characteristics.**

| Characteristic                                      | Case (N = 134) | Control (N = 292) | Total (N = 426) |
|-----------------------------------------------------|---------------|------------------|----------------|
| Age at parent study entry                           | 47 (40–53)    | 44 (39–50)       | 45 (39–51)     |
| Regimens evaluated, by parent study                 |               |                  |                |
| ACTG 384: (AZT + 3TC vs. d4T + ddI) + (EFV vs. NFV vs. NFV + EFV) | 40 (30%)      | 85 (29%)         | 125 (29%)      |
| ACTG 386: (AZT + 3TC vs. d4T + 3TC) + (IDV vs. NFV vs. IDV + NFV) | 62 (46%)      | 144 (49%)        | 206 (48%)      |
| A5014: NVP + (LPV/r vs. (ABC + 3TC + d4T)]          | 32 (24%)      | 63 (22%)         | 95 (22%)       |
| A5095: AZT/3TC + (ABC vs. EFV vs. ABC + EVF)        | 112 (84%)     | 247 (85%)        | 359 (84%)      |
| A5142: (EFV + AZT/d4T + 3TC) vs. (LPV/r + AZT/d4T + 3TC) vs. (EFV + LPV/r) | 70 (52%)      | 138 (47%)        | 208 (49%)      |
| A5202: (ABC/3TC vs. TFv/FTC) + (ATV/r vs. EVF)      | 48 (36%)      | 82 (28%)         | 131 (31%)      |
| Race/ethnicity                                      |               |                  |                |
| White non-Hispanic                                  | 60 (45%)      | 105 (36%)        | 165 (39%)      |
| Black non-Hispanic                                  | 70 (52%)      | 138 (47%)        | 208 (49%)      |
| Hispanic (regardless of race)                       | 15 (11%)      | 61 (21%)         | 76 (18%)       |
| Asian, Pacific Islander                             | 0 (0%)        | 6 (2%)           | 6 (1%)         |
| Native American, Alaskan native                     | 1 (1%)        | 2 (1%)           | 3 (1%)         |
| Participant does not know                           | 0 (0%)        | 1 (0%)           | 1 (0%)         |
| More than one race                                  | 0 (0%)        | 2 (1%)           | 2 (0%)         |
| Baseline CD4+ T-cell count (cells/µL)               | 207 (87–334)  | 220 (76–332)     | 213 (79–334)   |
| Baseline log_{10} HIV-1 RNA (copies/ml)             | 4.8 (4.4–5.3) | 4.8 (4.4–5.4)    | 4.8 (4.4–5.4)  |

Categorical variables are represented as frequency and continuous variables as median (Q1–Q3). 3TC, lamivudine; ABC, abacavir; ATV/r, ritonavir-boosted atazanavir; AZT, zidovudine; d4T, stavudine; ddI, didanosine; EFV, efavirenz; FTC, emtricitabine; IDV, indinavir; LPV/r, ritonavir-boosted lopinavir; NFV, nevirapine; NVP, nevirapine; TFV, tenofovir.
baseline (OR = 1.4, 0.7–2.8; P = 0.312). Furthermore, the association at year 1 remained significant with adjustment for CD4+ count (OR = 1.4, 1.0–1.9; P = 0.046). However, adjustment in other biomarkers previously linked to NAEs, particularly IL-6, TNFR1/II, and suPAR, attenuated Gal-9 associations (Supplementary Tables 2–4, http://links.lww.com/QAD/C258, http://links.lww.com/QAD/C259, http://links.lww.com/QAD/C260). When examining component-specific analyses by type of NAEs (Fig. 1c, Supplementary Table 5, http://links.lww.com/QAD/C261), higher year 1 Gal-9 levels were associated with increased risk of MI/stroke (n = 32 events; OR = 1.9, 1.1–3.4; P = 0.029); while not statistically significant, higher levels of Gal-9 was associated with increased risk of death (n = 14 events; OR = 2.8, 0.9–8.2; P = 0.069) at year 1 and increased risk of malignancy at preevent (n = 35 events; OR = 1.8, 1.0–3.3; P = 0.050).

Fig. 1. Plasma galectin-9 predicts non-AIDS events post-antiretroviral therapy initiation. (a) Distribution of plasma galectin-9 (Gal-9) among cases (blue) and controls (black) at each time point. Jitter plots including median and interquartile range (box), and minimum and maximum (vertical lines) are displayed. (b) Spearman correlations for galectin-9 with pre-ART factors and previously assessed biomarkers among controls; all correlations P less than 0.05; ribbon width is proportional to respective r value (range: 0.17–0.64); band color represents associated parameter; *Indicates inverse correlations. (c) Associations between galectin-9 levels and odds ratios (ORs) the occurrence of a non-AIDS event; adjusted analyses controlled for concurrent HIV viral load at baseline and CD4+ T-cell count at year 1 and preevent; *P less than 0.05, "P = 0.10 to less than 0.05. BDG, 1,3-β-D-glucan; I-FABP, intestinal fatty-acid binding protein; IL-6, Interleukin 6; IP-10, interferon gamma-induced protein 10; LBP, liposaccharide-binding protein; MI, myocardial infarction; suPAR, soluble urokinase plasminogen activator receptor; TNFR, tumor necrosis factor receptor.
Discussion

Given that PWH on effective ART remain at an increased risk in developing age-related comorbidities or death [1,2], reliable screening to mitigate risk and monitor interventions is required. Uncovering effective biomarkers that predict adverse HIV outcomes at any time during the disease course prior to or during ART are key in this regard. We show here that plasma Gal-9 associates with an increased risk of overall NAEs post-ART initiation despite significant decreases in levels after treatment, in line with previous studies of Gal-9 levels reflecting severe outcomes in infectious diseases and associating with multimorbidity and mortality risk in treated HIV [11,35]. Furthermore, we found that Gal-9 levels predicted MI/stroke 1 year after ART, of importance as PWH have a higher risk of developing coronary heart disease and Gal-9 is associated with cardiovascular outcomes in the general population [15,16]. Overall, our data suggests that Gal-9 may serve as a novel, predictive, and easily measurable marker to evaluate alone or incorporated in a biomarker composite panel to strengthen the monitoring of PWH at high risk and interventional studies.

Elevated levels of Gal-9 levels have been shown to correlate with multiple biomarkers of inflammation and immune activation previously linked to NAEs (i.e. sTNFRI/II, suPAR) [5,6]. Gal-9 itself is known to drive multiple immune pathways, including both the immunosuppression and proinflammatory cytokine induction of myeloid cells [36,37] and the impairment of T, B, and natural killer (NK) lymphocyte function [25,29,30]. Gal-9 can elicit pathways involved in apoptosis [26] and immune negative checkpoint activation [38–40], which are relevant to outcomes in HIV infection [41–44]. Investigating the cellular expression of Gal-9 ligands, including TIM-3 and Dectin-1, will contribute to understanding the pathogenic effect of elevated Gal-9. Interestingly, both Gal-9 and BDG bind Dectin-1 on myeloid cells [45,46]. As BDG is the main ligand of Dectin-1 on myeloid cells, and also predictive of NAEs at year 1, unraveling their intertwined pathways would be particularly interesting. Ultimately, unraveling the role Gal-9 may play in HIV-associated adverse outcomes would reveal whether modulation through targeting Gal-9 and/or Gal-9-induced pathways would prove valuable in altering the trajectory of disease. However, given proinflammatory cytokines can induce the cellular release of Gal-9 [47], it remains unclear whether elevations observed could merely be a consequence of residual inflammation that persists during infection.

Limitations to this study include that our analysis was restricted to PWH during chronic infection with low baseline CD4+ counts, limiting inference for patients today. Given comorbidity-free life expectancy is increased with early ART administration and rapid viral decline with current regimens that include integrase inhibitors [48,49], investigating whether Gal-9 still predicts NAEs following early modern ART intervention is warranted. Although Gal-9 was not significantly associated with NAEs at baseline, the effect size was notably consistent with our other findings and may be because of its strong link with viremia and immune suppression [9,12,34], as well as insufficient plasma for many participants at baseline. However, no major differences for baseline characteristics or Gal-9 levels were observed at year 1 among participants with a year 1 result who did or did not have one at baseline. We were also not able to evaluate Gal-9 changes from year 1 to preevent as the preevent time point varied across participants and sometimes occurred before year 1. Finally, the relative strength of the association between Gal-9 and disease outcomes were attenuated for and lower as compared with several previously assessed biomarkers, such as IL-6 and suPAR; although, calculated risks were relatively similar [5,6].

In conclusion, further dissecting Gal-9 pathways that interlink with viral persistence, immune activation, and inflammation leading to NAEs will determine the potential of Gal-9 as a target for intervention in the setting of suppressive ART. As Gal-9 is only one component of the emerging field of glycoimmunology, elucidating the importance of glycosylation and glycan–lectin interactions in HIV infection, particularly in the context of NAEs, should be pursued.

Acknowledgements

We would like to thank all study participants and clinical staff involved in the ALLRT study and the James B. Pendleton Charitable Trust.

Ethics approval and consent to participate: participants (or, for minors, their parent or legal guardian) provided written informed consent, and institutional review board approval for ALLRT was obtained by each ACTG site.

Availability of data and materials: Individual participant data and a data dictionary defining each field in the set will be made available to investigators on a case-by-case basis via request to the AIDS Clinical Trials Group (ACTG) via the link: https://submit.actnet.org/. Completion of an ACTG Data Use Agreement may be required.

Funding: Research reported in this publication was supported by the National Institute of Health grants UM1AI068634, UM1AI106701, UM1AI068636 (M.M.L.), R01MH112457 (L.C.N.), R01AI147821 (S.G.), DA051915 (S.G.), and UM1AI068634 (C.B.M., A.M.). Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author contributions: T.A.P. and L.C.N. wrote the manuscript; T.A.P. conducted soluble marker acquisition and data interpretation; C.B.M. and A.M. performed data analysis and interpretation; M.H., E.I.L., M.M.L., and A.L.L. provided critical review of the manuscript. L.C.N., C.B.M., and S.G. contributed to study design and concept. All authors reviewed the manuscript.

Conflicts of interest
L.C.N. has served on an advisory board for Abbvie, ViiV, and Cytodyn for work unrelated to this project. M.H. has received project funding from Gilead, Pfizer, and Astellas. All of the other authors have no conflicts of interest.

References
1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2015; 382:153–155.
2. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409–2418.
3. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39:631–645.
4. Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. AEGHV cohort study group. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AEGHV cohort study. Clin Infect Dis 2014; 59:1797–1807.
5. Hoenigl M, Moser CB, Funderburg N, Bosco R, Kantor A, Zhang Y, et al. Adult Clinical Trials Group NWCS 411 study team. Soluble urokinase plasminogen activator receptor is predictive of non-AIDS events during antiretroviral therapy-mediated viral suppression. Clin Infect Dis 2019; 69:676–686.
6. Tenorio AR, Zheng Y, Bosco RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbidity events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248–1259.
7. Colomb F, Giron LB, Trbojevic-Akmacic I, Lauc G, Abdel-Mohsen M. Breaking the Glyco-Code of HIV persistence and immunopathogenesis. Curr HIV/AIDS Rep 2019; 16:151–168.
8. Sato S, Ouelliet M, St-Pierre C, Tremblay MJ, Glycans, galectins, and HIV-1 infection. Ann N Y Acad Sci 2012; 1253:133–148.
9. Tandon R, Chew GM, Byron MM, Borrow P, Niki T, Hirashima M, et al. Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers. AIDS Res Hum Retroviruses 2014; 30:654–664.
10. Abdel-Mohsen M, Chavez L, Tandon R, Chew GM, Deng X, Danesh A, et al. Human galectin-9 is a potent mediator of HIV transcription and reactivation. PLoS Pathog 2016; 12:e1005677.
11. Premeaux TA, Javandel S, Hosaka KJ, Greene M, Therrien N, Allen JE, et al. Associations between plasma immunomodulatory and inflammatory mediators with VACS index scores among older HIV-infected adults on antiretroviral therapy. Front Immunol 2020; 11:1321.
12. Shete A, Dhayakar S, Dhananage A, Kulkarni S, Ghatre M, Sangal S, et al. Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings. AIDS Res Ther 2020; 17:43.
13. Kurose Y, Wada J, Kanazaki M, Teshigawara S, Nakatuka A, Murakami K, et al. Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease. BMC Nephrol 2013; 14:23.
14. Niki T, Fujita K, Rosen H, Hirashima M, Masaki T, Hattori T, Hoshino K. Plasma galectin-9 concentrations in normal and diseased condition. Cell Physiol Biochem 2018; 50:1856–1868.
15. Zhu R, Liu C, Tang H, Zeng Q, Wang X, Zhu Z, et al. Serum galectin-9 levels are associated with coronary artery disease in Chinese individuals. Mediators Inflamm 2015; 2015:457167.
16. He XW, Li WL, Li C, Liu P, Shen YG, Zhu M, Jin XP. Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke. Sci Rep 2017; 7:40984.
17. Brubel R, Bokor A, Pohl A, Schilli GK, Szeredny E, Bacher-Szamuely R, et al. Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. Fertil Steril 2017; 108:1016.e2–1025.e2.
18. Liang T, Wang X, Wang F, Feng E, You G. Galectin-9: a predictive biomarker negatively regulating immune response in glioma patients. World Neurosurg 2019; 132:e435–e462.
19. Liu Y, Liu Z, Fu Q, Wang Z, Fu H, Liu W, et al. Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma. Urol Oncol 2017; 33:349–355.
20. Matsuoka N, Fujita Y, Temmoku J, Furuya MY, Asano T, Sato S, et al. Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus. PLoS One 2020; 15:e0227069.
21. Seifert AM, Reische C, Heidkrüd M, Tammert A, Meinecke AC, Baier S, et al. Detection of galectin-9 with galectin-9 serum levels. Oncogene 2020; 39:3102–3113.
22. Siders K, de Man RA, Harrington SM, Polak WG, Zhou G, Schütz HM, et al. Circling levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumor expression levels. Sci Rep 2019; 9:10677.
23. van den Hoogen LL, van der Heijden EHM, Hillen MR, Mertens JS, Fritschi-Stork RDE, Radstake T, van Roon JAG. Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Response to: ‘Biomarkers: to be or not to be’ by Yavuz and Rombhom. Ann Rheum Dis 2020, 79.e9.
24. van den Hoogen LL, van Roon JAG, Mertens JS, Wienke J, Lopes AP, de Jager W, et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2018; 77:1810–1814.
25. Luullier C, Barjon C, Niki T, Gelin A, Praz F, Morales O, et al. Impact of exogenous galectin-9 on human T cells: contribution of the T cell receptor complex to antigen-independent activation but not to apoptosis induction. J Biol Chem 2015; 290:16797–16811.
26. Kashiyo Y, Nakamura K, Abden MJ, Seki M, Nishi N, Yoshida N, et al. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 2003; 170:3631–3636.
27. O’Hare PW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 2011; 21:1258–1265.
28. Lv K, Zhang Y, Zhang M, Zhong M, Suo Q. Galectin-9 promotes TGF-beta-dependent induction of regulatory T cells via the TGF-beta/Smad signaling pathway. Mol Med Rep 2013; 7:205–210.
29. Golden-Mason L, McMahan RH, Strong M, Reisdorph R, Malley S, Palmer BE, et al. Galectin-9 is an alternative activation marker on neutral killer cells in humans and mice. J Virol 2013; 87:4835–4845.
30. Giovannone N, Liang J, Antonopoulos A, Geddes Sweeney, King SL, Pocheht SM, et al. Galectin-9 suppresses B cell receptor signaling and is regulated by l-branching of N-glycans. Nat Commun 2018; 9:3287.
31. Chagam-Yasutan H, Shiratori B, Siddiqi UR, Saitoh H, Ashino Y, Arakawa T, et al. The increase of plasma galectin-9 in a patient with insulin allergy: a case report. Clin Mol Allergy 2010; 8:12.
32. Smurzynski M, Collier AC, Koletar SL, Bosch RJ, Wu K, Bastow B, Benson CA. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design and baseline characteristics. HIV Clin Trials 2008; 9:269–282.
33. Saitoh H, Ashino Y, Chagam-Yasutan H, Niki T, Hirashima M, Hattori T. Rapid decrease of plasma galectin-9 levels in patients with acute HIV infection after therapy. Tohoku J Exp Med 2012; 228:157–161.
34. Premeaux TA, D’Antoni ML, Abdel-Mohsen M, Pillai SK, Kaliamurthi K, Nakamoto RK, et al. Elevated soluble galectin-9 fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. J Neurovirol 2019; 25:150–161.
35. Iwasaki-Hozumi H, Chagan-Yasutan H, Ashino Y, Hattori T. Blood levels of galectin-9, an immuno-regulating molecule, reflect the severity for the acute and chronic infectious diseases. *Biomolecules* 2021; 11:430.

36. Arikawa T, Saita N, Oomizu S, Ueno M, Matsukawa A, Katoh S, et al. Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation. *Eur J Immunol* 2010; 40:548–558.

37. Matsuura A, Tsukada J, Mizobe T, Higashi T, Mouri F, Tanikawa R, et al. Intracellular galectin-9 activates inflammatory cytokines in monocytes. *Genes Cells* 2009; 14:511–521.

38. Komita H, Koido S, Hayashi K, Kan S, Ito M, Kamata Y, et al. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors. *Oncol Rep* 2015; 34:2099–2105.

39. Kursunel MA, Esendagli G. A co-inhibitory alliance in myeloid leukemia: TIM-3/Galectin-9 complex as a new target for checkpoint blockade therapy. *EBioMedicine* 2017; 23:6–7.

40. Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. *Nat Commun* 2021; 12:812.

41. Pitrak DL, Novak RM, Estes R, Tschampa J, Abaya CD, Martino J, et al. Short communication: apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery. *AIDS Res Hum Retroviruses* 2013; 31:208–216.

42. Kassu A, Marcus RA, D’Souza MB, Kelly-McKnight EA, Golden-Mason L, Akkina R, et al. Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. *J Immunol* 2010; 185:3007–3018.

43. Sakhdari A, Mujib S, Vali B, Yue FY, MacParland S, Clayton K, et al. Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. *PloS One* 2012; 7:e40146.

44. Velu V, Shetty RD, Lanson M, Shankar EM. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. *Retrovirology* 2015; 12:14.

45. Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, et al. Dectin-1 is a major beta-glucan receptor on macrophages. *J Exp Med* 2002; 196:407–412.

46. Daley D, Mani VR, Mohan N, Akkad N, Ochi A, Heindel DW, et al. Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. *Nat Med* 2017; 23:556–567.

47. Gieseke F, Kruchen A, Tzaribachev N, Bentzien F, Dominici M, Muller I. Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation. *Eur J Immunol* 2013; 43:2741–2749.

48. Marcus JL, Leyden WA, Alexeef SE, Anderson AN, Hechter RC, Hu H, et al. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016. *JAMA Netw Open* 2020; 3:e207954.

49. Trivedi J, Mahajan D, Jaffe RJ, Acharya A, Mitra D, Byrareddy SN. Recent advances in the development of integrase inhibitors for HIV treatment. *Curr HIV/AIDS Rep* 2020; 17:63–75.